Agricultural Supply Services Ltd Products » Equest Syringe Single Tube

Equest Syringe Single Tube

Equest Syringe Single Tube

Presentation
A clear gel containing 18.92 mg/g moxidectin and 37.84 mg/g benzyl alcohol and 0.24 mg/g disodium edetate as preservatives.

Uses
Moxidectin is a second generation macrocyclic lactone of the milbemycin family.
For the treatment and control of adult and larval stages of important internal parasites including encysted inhibited EL3 and developing intramucosal L4 larval stages of small redworms, arterial stages of large redworms and bots in horses and ponies with a single dose.
EQUEST Oral Gel, at the recommended dosage level of 400 mcg moxidectin per kg bodyweight, provides effective control of moxidectin sensitive strains of the following parasites of horses and ponies:
Large strongyles:
Strongylus vulgaris (adults and arterial stages)
Strongylus edentatus (adults and visceral stages)
Triodontophorus brevicauda (adults)
Triodontophorus serratus (adults)
Triodontophorus tenuicollis (adults)
Small strongyles (adults and intraluminal larval stages):
Cyathostomum spp.
Cylicocyclus spp.
Cylicostephanus spp.
Cylicodontophorus spp.
Gyalocephalus spp.
EQUEST Oral Gel is effective against (developing) intramucosal L4 stages of small strongyles. At eight weeks after treatment early (hypobiotic) EL3 stages of small strongyles are eliminated.
EQUEST Oral Gel is effective against benzimidazole resistant strains of cyathostomes.
Ascarids:
Parascaris equorum (adult and larval stages)
Other species:
Oxyuris equi (adult and larval stages)
Habronema muscae (adults)
Gasterophilus intestinalis (L2, L3)
Gasterophilus nasalis (L2, L3)
Strongyloides westeri (adults)
Trichostrongylus axei
EQUEST Oral Gel has a persistent effect in preventing infection by small strongyles for 2 weeks after dosing and suppresses the presence of small strongyle eggs in the dung for 90 days.

Dosage and administration
For oral administration. One 12.2g syringe contains sufficient gel to treat one 575 kg horse at the recommended dose rate (0.4 mg moxidectin per kg bodyweight). Each graduation on the calibrated syringe delivers sufficient gel to treat 25 kg bodyweight. Use of a scale or weigh tape is recommended to ensure accurate dosing. To avoid overdosing, care should be taken to accurately dose foals, especially low bodyweight foals or young ponies.
Dosing guideline
The persistent activity of EQUEST Oral Gel and its effectiveness against inhibited and developing larvae in the intestinal mucosa enables a reduction in the dosing frequency in strategic parasite control programmes. The recommended dosing interval for the control of small strongyles is 13 weeks. Consult your veterinary surgeon for the appropriate programme for your specific needs.

Contra-indications, warnings, etc
Horses must not be slaughtered for human consumption within 32 days of treatment.
Do not administer to young foals less than 4 months of age.
EQUEST Oral Gel is formulated specifically for use in horses only. Dogs or cats may be adversely affected by the concentration of moxidectin in this product if they are allowed to ingest spilled gel or have access to used syringes.
Do not administer in case of known hypersensitivity to the active ingredient or to any other milbemycins and to any other ingredients of the veterinary medicinal product.
Do not use the same syringe to treat more than one animal unless horses are running together or in direct contact with each other on the same premises.

£11.50 Ex Vat